Zacks Research Brokers Boost Earnings Estimates for STERIS

STERIS plc (NYSE:STE - Free Report) - Zacks Research upped their Q3 2026 EPS estimates for STERIS in a research note issued on Thursday, June 12th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.65 for the quarter, up from their previous estimate of $2.53. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's Q4 2026 earnings at $2.86 EPS, FY2026 earnings at $10.36 EPS, Q4 2027 earnings at $2.78 EPS and FY2028 earnings at $12.38 EPS.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, beating the consensus estimate of $2.59 by $0.15. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The firm had revenue of $1.48 billion during the quarter, compared to analysts' expectations of $1.47 billion. During the same quarter in the prior year, the firm posted $2.58 EPS. The company's revenue for the quarter was up 5.7% on a year-over-year basis.

STE has been the topic of several other research reports. JMP Securities boosted their price target on shares of STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a report on Friday, May 16th. Wall Street Zen raised shares of STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Stephens reissued an "overweight" rating and issued a $250.00 price target on shares of STERIS in a research report on Thursday, May 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. Finally, Jefferies Financial Group started coverage on STERIS in a report on Thursday, May 29th. They issued a "hold" rating and a $263.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $263.83.

STERIS Stock Performance

Shares of NYSE STE traded down $0.93 during trading hours on Monday, reaching $236.15. The stock had a trading volume of 540,879 shares, compared to its average volume of 548,329. The company has a market cap of $23.23 billion, a price-to-earnings ratio of 38.09 and a beta of 0.94. STERIS has a twelve month low of $200.98 and a twelve month high of $252.79. The business's fifty day moving average is $233.97 and its two-hundred day moving average is $223.10. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 0.97%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's payout ratio is 36.77%.

Insider Activity

In other STERIS news, CEO Daniel A. Carestio sold 17,626 shares of the stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the sale, the chief executive officer now owns 51,385 shares of the company's stock, valued at $12,463,945.60. This represents a 25.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Cary L. Majors sold 12,828 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company's stock, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

Several hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its position in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Avalon Trust Co bought a new stake in shares of STERIS during the fourth quarter worth $30,000. Human Investing LLC acquired a new position in shares of STERIS during the fourth quarter valued at $31,000. Grove Bank & Trust boosted its holdings in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 142 shares during the last quarter. Finally, Anfield Capital Management LLC increased its position in STERIS by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares during the period. 94.69% of the stock is owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.